• About us
• Contact

Advertisement

Organisation › Details

Autifony Therapeutics Ltd.

Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat hearing disorders and other serious diseases of the central nervous system. It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc. *

 

	Start	2011-01-01 splitoff
	Group	Autifony (Group)
	Predecessor	GSK (Group)
	Industry	drug discovery
	Person	Large, Charles (Autifony 201712 CEO before CSO)
	Region	Stevenage, Hertfordshire
	Country	United Kingdom (GB)
	Street	Gunnels Wood Road Stevenage Bioscience Catalyst
	City	SG1 2FX Stevenage, Hertfordshire
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Autifony Therapeutics Ltd.. (8/26/20). "Press Release: Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme". Stevenage.
		Record changed: 2023-11-16

Advertisement

More documents for Autifony (Group)

• [1] Autifony Therapeutics Ltd.. (11/14/23). "Press Release: Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders". Stevenage....
• [2] Autifony Therapeutics Ltd.. (3/4/21). "Press Release: Autifony Therapeutics, Boehringer Ingelheim to Collaborate On Novel Ion Channel Target with Potential in Multiple Disease Areas Related to Lysosomal Storage Disorders". Stevenage....
• [3] Autifony Therapeutics Ltd.. (8/26/20). "Press Release: Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme". Stevenage....
• [4] Autifony Therapeutics Ltd.. (1/18/19). "Press Release: Autifony Therapeutics Achieves First Milestone in Agreement with Boehringer Ingelheim for a Novel Therapeutic Approach to a Range of CNS Disorders". Stevenage....
• [5] Boehringer Ingelheim. (12/18/17). "Press Release: Autifony Therapeutics and Boehringer Ingelheim Collaborate on a Novel Therapeutic Approach to a Range of CNS Disorders". Stevenage & Ingelheim....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.